Grupo de Investigación en Cáncer de Mama
NEONCOBREAST
Cancer Research UK
Londres, Reino UnidoPublications in collaboration with researchers from Cancer Research UK (2)
2020
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12